Novavax, Inc. (NASDAQ:NVAX) currently has a “Hold” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Novavax, Inc. (NASDAQ:NVAX) closed its previous trading session at $2.15. The stock traded with the average Volume of 12.09 Million at the end of last session.
Novavax, Inc. (NASDAQ:NVAX) has the Market Capitalization of 667.75 Million. The Stock has its 52-week High of $2.75 and 52-Week Low of $0.73 and it touched its 52-week high on 03/01/18 and 52-Week Low on 05/08/17.
The company reported its last earnings Actual EPS of $-0.15/share. While, the analyst predicted that the company could provide an EPS of $-0.16/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 6.3 Percent.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated Novavax, Inc. (NASDAQ:NVAX) as Buy, 0 analysts given Outperform signal, 2 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -1.31% where SMA50 and SMA200 are 9.71% and 58.77% respectively.
The company shows its Return on Assets (ROA) value of -52.6%. The Return on Equity (ROE) value stands at 452.8%.
Novavax, Inc. (NASDAQ:NVAX) currently has a Weekly Volatility of 4.31% percent while its Monthly Volatility is at 8.32% percent. While talking about Performance of the Stock, Novavax, Inc. currently has a Weekly performance of 6.97%, monthly performance percentage is 8.59 percent, Quarterly performance is 50.35 percent, 6 months performance shows a percent value of 86.96% and Yearly Performance is 49.31 percent.
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.